Syndecan-4 (synd4) is a
heparan sulfate proteoglycan, involved in repair following tissue damage, through modulating neovascularization and
inflammation. In acute
myocardial infarction its myocardial expression is up-regulated in a time-dependent manner, and in synd4-deficient mice severe cardiac dysfunction and abnormal remodeling are observed following induction of
myocardial infarction. Here we explored the therapeutic potential of sustained synd4 over-expression in the context of
myocardial infarction. Adenovirus containing the synd4 gene (Ad-synd4), or corresponding control adenovirus (Ad-null), was administered intramyocardially in rats immediately after induction of
myocardial infarction. Cardiac function was ascertained by echocardiography, hemodynamic assessment and
brain natriuretic peptide level 28 days post-intervention. Hearts were excised for molecular and histological analyses at predetermined time points. We observed reduced mortality and improved cardiac function post-
myocardial infarction in the Ad-synd4 as compared to the Ad-null group, with associated attenuation of cardiac remodeling, less myocyte loss and reduced
fibrosis. Additionally, the Ad-synd4 group exhibited endothelial cell activation and increased angiogenesis and arteriogenesis in the myocardium. The Ad-synd4 group also showed evidence of reduced myocardial
inflammation as compared with the Ad-null group, with reduced inflammatory cell (CD45+) and myofibroblast (α-SMA+) infiltration as well as suppressed
collagen III deposition and iNOS expression. Our results suggest that sustained synd4 over-expression in the myocardium is of therapeutic benefit following experimental
myocardial infarction, through inducing neovascularization, suppressing tissue
inflammation and
fibrosis, with resultant improvements in cardiac function and remodeling.